All Stories

  1. Aminochrome-Induced Disruption of Autophagosome-Lysosome Fusion: Implications for Protein Aggregation in Parkinson’s Disease
  2. A Potential Role of Natural Bioactive Compounds Found in Food in the Prevention of Idiopathic Parkinson’s Disease
  3. On the Role of Iron in Idiopathic Parkinson’s Disease
  4. Why are neuromelanin-containing dopaminergic neurons lost in idiopathic Parkinson’s disease?
  5. Single-neuron neurodegeneration as a degenerative model for Parkinson’s disease
  6. A Preclinical Model for Parkinson’s Disease Based on Transcriptional Gene Activation via KEAP1/NRF2 to Develop New Antioxidant Therapies
  7. Neuroprotection against Aminochrome Neurotoxicity: Glutathione Transferase M2-2 and DT-Diaphorase
  8. Generation of nonviral integration-free human iPS cell line KISCOi001-A from normal human fibroblasts, under defined xeno-free and feeder-free conditions
  9. Cellular Trafficking of Glutathione Transferase M2-2 Between U373MG and SHSY-S7 Cells is Mediated by Exosomes
  10. State and perspectives on flavonoid neuroprotection against aminochrome-induced neurotoxicity
  11. The Flavonoid Agathisflavone from Poincianella pyramidalis Prevents Aminochrome Neurotoxicity
  12. The importance of choosing a preclinical model that reflects what happens in Parkinson's disease
  13. DT-Diaphorase Prevents Aminochrome-Induced Lysosome Dysfunction in SH-SY5Y Cells
  14. Can we conclude a potential therapeutic action for Parkinson’s disease by using postmortem tissue and a preclinical model based on an exogenous neurotoxin?
  15. P1‐159: RARE VARIANTS IN PLCG2, ABI3, AND TREM2 GENES ARE ASSOCIATED WITH ALZHEIMER'S DISEASE IN AN ARGENTINIAN SAMPLE: IS IT A EUROPEAN HERITAGE?
  16. Comment on: “Activating Autophagy as a Therapeutic Strategy for Parkinson’s Disease”
  17. Aminochrome decreases NGF, GDNF and induces neuroinflammation in organotypic midbrain slice cultures
  18. Aminochrome Induces Irreversible Mitochondrial Dysfunction by Inducing Autophagy Dysfunction in Parkinson's Disease
  19. Neurotoxins as Preclinical Models for Parkinson’s Disease
  20. KM-34, a Novel Antioxidant Compound, Protects against 6-Hydroxydopamine-Induced Mitochondrial Damage and Neurotoxicity
  21. The Importance of Mitophagy in Maintaining Mitochondrial Function in U373MG Cells. Bafilomycin A1 Restores Aminochrome-Induced Mitochondrial Damage
  22. Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease
  23. Aminochrome induces microglia and astrocyte activation
  24. Knockdown of Myo-Inositol Transporter SMIT1 Normalizes Cholinergic and Glutamatergic Function in an Immortalized Cell Line Established from the Cerebral Cortex of a Trisomy 16 Fetal Mouse, an Animal Model of Human Trisomy 21 (Down Syndrome)
  25. Aminochrome as preclinical model for Parkinson's disease
  26. Commentary: Gene Therapy: A Promising Approach for Neuroprotection in Parkinson's Disease?
  27. DT-diaphorase Protects Against Autophagy Induced by Aminochrome-Dependent Alpha-Synuclein Oligomers
  28. New preclinical model are required to discover neuroprotective compound in Parkinson’s disease
  29. On the Role of Mining Exposure in Epigenetic Effects in Parkinson’s Disease
  30. On the Role of DT-Diaphorase Inhibition in Aminochrome-Induced Neurotoxicity In Vivo
  31. Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson’s Disease?
  32. Autophagy protects against neural cell death induced by piperidine alkaloids present in Prosopis juliflora (Mesquite)
  33. On the role of endogenous neurotoxins and neuroprotection in Parkinson's disease
  34. Corrigendum: Commentary: Evaluation of Models of Parkinson's Disease
  35. DT-diaphorase protects astrocytes from aminochrome-induced toxicity
  36. Commentary: A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease
  37. Commentary: Evaluation of Models of Parkinson's Disease
  38. Aminochrome induces dopaminergic neuronal dysfunction: a new animal model for Parkinson’s disease
  39. Impact of Plant-Derived Flavonoids on Neurodegenerative Diseases
  40. Aminochrome as New Preclinical Model to Find New Pharmacological Treatment that Stop the Development of Parkinson’s Disease
  41. Erratum
  42. The need of a new and more physiological preclinical model for Parkinson’s disease
  43. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
  44. Aminochrome Toxicity is Mediated by Inhibition of Microtubules Polymerization Through the Formation of Adducts with Tubulin
  45. Neurotoxin Mechanisms and Processes Relevant to Parkinson’s Disease: An Update
  46. DT-Diaphorase Prevents Aminochrome-Induced Alpha-Synuclein Oligomer Formation and Neurotoxicity
  47. A new mechanism for protection of dopaminergic neurons mediated by astrocytes
  48. Molecular and Neurochemical Mechanisms Dopamine Oxidation To O-Quinones in Parkinson’s Disease Pathogenesis
  49. Glutathione Transferase-M2-2 Secreted from Glioblastoma Cell Protects SH-SY5Y Cells from Aminochrome Neurotoxicity
  50. Protective and toxic roles of dopamine in Parkinson's disease
  51. Glutathione transferase mu 2 protects glioblastoma cells against aminochrome toxicity by preventing autophagy and lysosome dysfunction
  52. Advances in Stem Cell Research for Parkinson Disease
  53. Dopamine and L-dopa as Selective Endogenous Neurotoxins
  54. Mechanisms of Dopamine Oxidation and Parkinson’s Disease
  55. RCSN Cell System for Identifying Dopaminergic Neurotoxicity
  56. One-Electron Reduction of 6-Hydroxydopamine Quinone is Essential in 6-Hydroxydopamine Neurotoxicity
  57. Frequency of the D620N Mutation in VPS35 in Parkinson Disease
  58. Erratum to: Protective Effects of Nicotine Against Aminochrome-Induced Toxicity in Substantia Nigra Derived Cells: Implications for Parkinson’s Disease
  59. Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity
  60. Protective Effects of Nicotine Against Aminochrome-Induced Toxicity in Substantia Nigra Derived Cells: Implications for Parkinson’s Disease
  61. Guidelines for the use and interpretation of assays for monitoring autophagy
  62. Targeting the UPR transcription factor XBP1 protects against Huntington's disease through the regulation of FoxO1 and autophagy
  63. The dopamine metabolite aminochrome inhibits mitochondrial complex I and modifies the expression of iron transporters DMT1 and FPN1
  64. Dopamine Oxidation and Autophagy
  65. The role of metal ions in dopaminergic neuron degeneration in Parkinsonism and Parkinson’s disease
  66. Altered Voltage Dependent Calcium Currents in a Neuronal Cell Line Derived From the Cerebral Cortex of a Trisomy 16 Fetal Mouse, an Animal Model of Down Syndrome
  67. Lrrk2 p.Q1111H substitution and Parkinson’s disease in Latin America
  68. ChemInform Abstract: The Role of Metal Ions in Dopaminergic Neuron Degeneration in Parkinsonism and Parkinson′s Disease
  69. The role of metal ions in dopaminergic neuron degeneration in Parkinsonism and Parkinson’s disease
  70. Autophagy Protects Against Aminochrome-Induced Cell Death in Substantia Nigra-Derived Cell Line
  71. Catecholaminergic Cell Lines for the Study of Dopamine Metabolism and Neurotoxicity
  72. Association of Parkinson disease to PARK16 in a Chilean sample
  73. Stable Expression of Short Interfering RNA for DT-Diaphorase Induces Neurotoxicity
  74. Erratum to: Aminochrome Induces Disruption of Actin, Alpha-, and Beta-Tubulin Cytoskeleton Networks in Substantia-Nigra-Derived Cell Line
  75. Aminochrome Induces Disruption of Actin, Alpha-, and Beta-Tubulin Cytoskeleton Networks in Substantia-Nigra-Derived Cell Line
  76. Diagnóstico genético disponible para la enfermedad de huntington en chile
  77. IV Neurotoxicity Society Meeting: Neurochemical Mechanisms of Neurodegenerative Disorders
  78. Molecular and Neurochemical Mechanisms in PD Pathogenesis
  79. Copper·Dopamine Complex Induces Mitochondrial Autophagy Preceding Caspase-independent Apoptotic Cell Death
  80. Chapter 4 Molecular Aspects of Neurotoxins in Dopaminergic Neurons
  81. The catecholaminergic RCSN-3 cell line: A model to study dopamine metabolism
  82. Copper Neurotoxicity in Rat Substantia Nigra and Striatum Is Dependent on DT-Diaphorase Inhibition
  83. Erratum
  84. Effect of the knockdown of amyloid precursor protein on intracellular calcium increases in a neuronal cell line derived from the cerebral cortex of a trisomy 16 mouse
  85. Botulinum neurotoxin: Evolution from poison, to research tool - onto medicinal therapeutic and future pharmaceutical panacea
  86. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease
  87. Aminochrome as a preclinical experimental model to study degeneration of dopaminergic neurons in Parkinson’s disease
  88. Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component
  89. Inhibition of VMAT-2 and DT-Diaphorase Induce Cell Death in a Substantia Nigra-Derived Cell LineAn Experimental Cell Model for Dopamine Toxicity Studies
  90. Neurotoxins and neurotoxicity mechanisms. an overview
  91. Knockdown of amyloid precursor protein normalizes cholinergic function in a cell line derived from the cerebral cortex of a trisomy 16 mouse: An animal model of down syndrome
  92. Dopamine-Dependent Iron Toxicity in Cells Derived from Rat Hypothalamus
  93. Monoamine transporter inhibitors and norepinephrine reduce dopamine-dependent iron toxicity in cells derived from the substantia nigra
  94. Cell Lines as In Vitro Models for Drug Screening and Toxicity Studies
  95. On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation
  96. Behavioral effects of manganese injected in the rat substantia nigra are potentiated by dicumarol, a DT-diaphorase inhibitor
  97. Neurotoxins and neurotoxic species implicated in neurodegeneration
  98. Effects of the DT-diaphorase inhibitor dicumarol on striatal monoamine levels in L-DOPA and L-deprenyl pre-treated rats
  99. Inhibition of DT-Diaphorase potentiates thein vivo neurotoxic effect of intranigral injection of salsolinol in rats
  100. MPP+-induced degeneration is potentiated by dicoumarol in cultures of the RCSN-3 dopaminergic cell line. Implications of neuromelanin in oxidative metabolism of dopamine neurotoxicity
  101. Novel mechanisms and approaches in the study of neurodegeneration and neuroprotection. A review
  102. Behavioral effects of aminochrome and dopachrome injected in the rat substantia nigra
  103. Establishment and characterization of immortalized neuronal cell lines derived from the spinal cord of normal and trisomy 16 fetal mice, an animal model of Down syndrome
  104. Neurotoxicological and neuroprotective elements in Parkinson’s disease
  105. Inhibition of DT-diaphorase is a requirement for Mn3+ to produce a 6-OH-dopamine like rotational behaviour
  106. Neurotoxicity of some MAO inhibitors in adult rat hypothalamic cell culture
  107. Copper neurotoxicity is dependent on dopamine-mediated copper uptake and one-electron reduction of aminochrome in a rat substantia nigra neuronal cell line
  108. Possible Role of Salsolinol Quinone Methide in the Decrease of RCSN-3 Cell Survival
  109. THE PRICE OF DEVELOPMENT IN CHILE
  110. The possible role of one-electron reduction of aminochrome in the neurodegenerative process of the dopaminergic system
  111. Glutathione Transferase M2-2 Catalyzes Conjugation of Dopamine and Dopa o-Quinones
  112. Reduction of Brain Antioxidant Defense Upon Treatment with Butylated Hydroxyanisole (BHA) and Sudan III in Syrian Golden Hamster
  113. Regioselectivity and Reversibility of the Glutathione Conjugation of Quercetin Quinone Methide
  114. Role of redox cycling and activation by DT-diaphorase in the cytotoxicity of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB-1954) and its analogs
  115. Interplay Between CYP3A-Mediated Metabolism and Polarized Efflux of Terfenadine and Its Metabolites in Intestinal Epithelial Caco-2 (TC7) Cell Monolayers
  116. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product
  117. DT-diaphorase catalyzes N-denitration and redox cycling of tetryl
  118. Metabolic activation of dopamine o-quinones to o-semiquinones by NADPH cytochrome P450 reductase may play an important role in oxidative stress and apoptotic effects
  119. Quantitative structure activity relationships for the conversion of nitrobenzimidazolones and nitrobenzimidazoles by DT-diaphorase: implications for the kinetic mechanism
  120. Nitrobenzimidazoles as Substrates for DT-Diaphorase and Redox Cycling Compounds: Their Enzymatic Reactions and Cytotoxicity
  121. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes
  122. Effects of Four Organohalogen Environmental Contaminants on Cytochrome P450 Forms That Catalyze 4- and 2-Hydroxylation of Estradiol in the Rat Liver
  123. Human Class Mu Glutathione Transferases, in Particular Isoenzyme M2-2, Catalyze Detoxication of the Dopamine Metabolite Aminochrome
  124. The two-electron quinone reductase DT-diaphorase generates and maintains the antioxidant (reduced) form of coenzyme Q in membranes
  125. DT-Diaphorase Maintains the Reduced State of Ubiquinones in Lipid Vesicles thereby Promoting their Antioxidant Function
  126. Peroxidase Activity of Liver Microsomal Vitamin D 25-Hydroxylase and Cytochrome P450 1A2 Catalyzes 25-Hydroxylation of Vitamin D3and Oxidation of Dopamine to Aminochrome
  127. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems.
  128. Effects of Superoxide Dismutase and Catalase during Reduction of Adrenochrome by DT-Diaphorase and NADPH-Cytochrome P450 Reductase
  129. Studies on the mode of action of the herbicidal effect of 2,4,5-trichlorophenoxyacetic acid on germinating Norway spruce
  130. Superoxide Dismutase and Catalase Enhance Autoxidation during One-Electron Reduction of Aminochrome by NADPH-Cytochrome P-450 Reductase
  131. Superoxide dismutase and catalase prevent the formation of reactive oxygen species during reduction of cyclized dopa ortho-quinone by DT-diaphorase
  132. The protective effect of superoxide dismutase and catalase against formation of reactive oxygen species during reduction of cyclized norepinephrine ortho-quinone of DT-diaphorase
  133. Activity and immunohistochemistry of DT-diaphorase in hamster and human kidney tumours
  134. A new direct method for determining superoxide dismutase activity by measuring hydrogen peroxide formation
  135. The Effect of 5OH-1,4-Naphthoquinone on Norway Spruce Seeds during Germination
  136. The cytotoxic effects of 5-OH-1,4-naphthoquinone and 5,8-diOH-1,4-naphthoquinone on doxorubicin-resistant human leukemia cells (HL-60)
  137. Separation and characterization of isoforms of DT-diaphorase from rat liver cytosol
  138. Oxygen toxicity in the nervous tissue: Comparison of the antioxidant defense of rat brain and sciatic nerve
  139. Antioxidant and glutathione-related enzymatic activities in rat sciatic nerve
  140. The levels of quinone reductases, superoxide dismutase and glutathione-related enzymatic activities in diethylstilbestrol-induced carcinogenesis in the kidney of male Syrian golden hamsters
  141. On the mechanism of the Mn3+-induced neurotoxicity of dopamine: Prevention of quinone-derived oxygen toxicity by DT diaphorase and superoxide dismutase
  142. DT-diaphorase-catalyzed two-electron reduction of various p-benzoquinone- and 1,4-naphthoquinone epoxides
  143. Effect of superoxide dismutase on the autoxidation of various hydroquinones—A possible role of superoxide dismutase as a superoxide: Semiquinone oxidoreductase
  144. DT-diaphorase-catalyzed two electron reduction of quinone epoxides
  145. Dicoumarol-sensitive glucuronidation of benzo(a)pyrene metabolites in rat liver microsomes